Literature DB >> 21885612

Confocal imaging studies cast doubt on nuclear localization of JAK2V617F.

François Girodon, Mara P Steinkamp, Cédric Cleyrat, Sylvie Hermouet, Bridget S Wilson.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21885612      PMCID： PMC4131456          DOI： 10.1182/blood-2011-02-336479

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

1.  Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia.

Authors:  Ciro R Rinaldi; Paola Rinaldi; Adele Alagia; Marica Gemei; Nicola Esposito; Fabio Formiggini; Vincenzo Martinelli; Vitalyi Senyuk; Giuseppina Nucifora; Fabrizio Pane
Journal:  Blood       Date:  2010-09-22       Impact factor: 22.113

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase.

Authors:  P A Ram; D J Waxman
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

4.  Constitutive nuclear localization of Janus kinases 1 and 2.

Authors:  P E Lobie; B Ronsin; O Silvennoinen; L A Haldosén; G Norstedt; G Morel
Journal:  Endocrinology       Date:  1996-09       Impact factor: 4.736

5.  Janus kinase (Jak) subcellular localization revisited: the exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak.receptor complex to be equivalent to a receptor tyrosine kinase.

Authors:  Iris Behrmann; Tanja Smyczek; Peter C Heinrich; Hildegard Schmitz-Van de Leur; Waraporn Komyod; Bernd Giese; Gerhard Müller-Newen; Serge Haan; Claude Haan
Journal:  J Biol Chem       Date:  2004-05-03       Impact factor: 5.157

6.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962
  6 in total
  9 in total

Review 1.  Biology and significance of the JAK/STAT signalling pathways.

Authors:  Hiu Kiu; Sandra E Nicholson
Journal:  Growth Factors       Date:  2012-02-20       Impact factor: 2.511

2.  JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.

Authors:  Jennifer Jay; Alan Hammer; Andrea Nestor-Kalinoski; Maria Diakonova
Journal:  Mol Cell Biol       Date:  2014-10-20       Impact factor: 4.272

3.  Mpl traffics to the cell surface through conventional and unconventional routes.

Authors:  Cédric Cleyrat; Anza Darehshouri; Mara P Steinkamp; Mathias Vilaine; Daniela Boassa; Mark H Ellisman; Sylvie Hermouet; Bridget S Wilson
Journal:  Traffic       Date:  2014-07-18       Impact factor: 6.215

4.  Nuclear JAK2.

Authors:  Mark A Dawson; Andrew J Bannister; Lindsay Saunders; Omar-Abdel Wahab; Fan Liu; Stephen D Nimer; Ross L Levine; Berthold Göttgens; Tony Kouzarides; Anthony R Green
Journal:  Blood       Date:  2011-12-22       Impact factor: 22.113

5.  JAK Kinases in Health and Disease: An Update.

Authors:  Arian Laurence; Marko Pesu; Olli Silvennoinen; John O'Shea
Journal:  Open Rheumatol J       Date:  2012-09-07

6.  The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours.

Authors:  S J Thomas; J A Snowden; M P Zeidler; S J Danson
Journal:  Br J Cancer       Date:  2015-07-07       Impact factor: 7.640

7.  The SH2 domain and kinase activity of JAK2 target JAK2 to centrosome and regulate cell growth and centrosome amplification.

Authors:  Aashirwad Shahi; Jacob Kahle; Chandler Hopkins; Maria Diakonova
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.752

Review 8.  Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.

Authors:  Maria Teresa Bochicchio; Valeria Di Battista; Pietro Poggio; Giovanna Carrà; Alessandro Morotti; Mara Brancaccio; Alessandro Lucchesi
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

Review 9.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.